The details of the posters are as follows:
In collaboration with
Title | Expansion and Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes (TIL) from Metastatic Colorectal (CRC) and GI Cancers |
Authors | |
Presentation Type | Poster |
Session Date and Time | |
Abstract Number | 346 |
Title | Enhancing Directly Selected Tumor-Reactive TIL Function Through Genetic Modification |
Authors | |
Presentation Type | Poster |
Session Date and Time | |
Abstract Number | 350 |
In collaboration with Illumina, Inc.
Title | Tumor Neoantigen Prioritization from Liquid Biopsy Whole Exome Sequencing for Selected Tumor-Infiltrating Lymphocyte Therapy |
Authors | Urminder Singh, |
Presentation Type | Poster |
Session Date and Time | |
Abstract Number | 178 |
Title | TBio BFX 4101: A Neoantigen Prioritization Pipeline for Selected Tumor-Infiltrating Lymphocyte Therapy |
Authors | |
Presentation Type | Poster |
Session Date and Time | |
Abstract Number | 900 |
About Turnstone
Forward-Looking Statements
This press release contains forward-looking statements that are based on the beliefs and assumptions of our management team, and on information currently available to such management team. These forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control. All statements, other than statements of historical fact, contained in this press release, including statements regarding future events, future financial performance, business strategy and plans, and objectives of ours for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will” or “would,” or the negative of these terms or other comparable terminology. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results, levels of activity, performance or achievements of and those of our industry to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on any forward-looking statement. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this press release are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. We undertake no obligation to update or revise publicly any of the forward-looking statements after the date hereof to conform the statements to actual results or changed expectations except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. This press release discusses product candidates that are under clinical study and which have not yet been approved for marketing by the
Contact
Ahmed Aneizi
Investor Relations
(347) 897-5988
ahmed.aneizi@turnstonebio.com
Source:
2023 GlobeNewswire, Inc., source